NeuroThera Labs Inc., in which SciSparc Ltd. holds a controlling interest of about 75%, advanced its collaboration with Clearmind Medicine Inc. through the publication of an international PCT patent application for a novel combination therapy using 5-methoxy-2-aminoindane (MEAI) and palmitoylethanolamide (PEA) aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.
Comments